Grindeks                                                          08.08.2005



JSC Grindeks enter into  a supportive  investment agreement which provides 

granting 1,5 millions of Ls  from EU Development funds



On the 5th of August JSC Grindeks signed a contract with the Latvia Investment 

and Development Agency (LIDA) which   provides granting a supporting investment 

of 1.5 millions of Ls from the EU Development funds. This sum of money is tailored 

to development of the analytic scaling laboratory of Active pharmaceutical 

ingredients. The total expenses of the project are estimated to amount to 3,26  

millions of Ls.



The new scaling laboratory will comply with the requirements of the Good 

Manufacturing Practice –cGMP (Current Good Manufacturing Practice), having a good 

performance of all the devices and appliances and ensuring the quality of the 

controlling process. The new laboratory will be fit for production of the active 

pharmaceutical ingredients for industry and for clinical trials use.



The project will render to Latvian scientists the opportunity to perform a great 

part of researches, including clinical trials, here in Latvia. The Institute of Organic 

Synthesis (IOS), LTd Medpro, JSC Riga Pharmaceutical plant and JSC LMP are interested 

in realization of this project as well.



This will be the first laboratory meeting the CGMP standards in the Baltic States.

It is planned to finish the construction of Active pharmaceutical ingredients analytic 

scaling laboratory in May 2007.

 

Information prepared by:

Finance and Administrative director

JSC Grindeks

Office: 7083250, 

GSM:  9226767

e-mail: janis_romanovskis@grindeks.lv